TLDRModerna shares climbed 2.2% to $193.15 in premarket hours Friday after Nasdaq confirmed the biotech’s October 9 addition to the Nasdaq-100 Index.The company takes the spot vacated by Warner Bros. Discovery, which exits the index due to its $81 billion acquisition by Paramount Skydance closing October 6.Year-to-date, MRNA has soared approximately 553%, lifting its market capitalization to around $75.4 billion.Citi’s Geoff Meacham cut his rating to Sell, arguing the stock’s valuation far exceeds what the company’s cancer pipeline can realistically deliver.Analysts collectively assign a Hold rating to MRNA, with an average price target suggesting roughly 42% downside from current levels.Moderna shares advanced 2.2% in Friday’s premarket session, reaching $193.15, after Nasdaq formally announced the biotech will enter the Nasdaq-100 Index ahead of the October 9 opening bell.Moderna, Inc., MRNAThis isn’t a clinical development driving the move. It’s pure index arithmetic.Moderna fills the vacancy left by Warner Bros. Discovery, which is exiting following its acquisition by Paramount Skydance in an $81 billion transaction. A federal court recently greenlit a settlement that removed the final obstacle to the deal, slated to finalize on October 6.When Moderna officially joins the index, passive funds tracking the Nasdaq-100 will be forced to purchase shares. With more than $800 billion in assets benchmarked to the index, even modest position adjustments generate significant demand.An Unprecedented Run for MRNAModerna has delivered one of the year’s most dramatic stock performances. Shares have surged approximately 553% since the start of January, propelling the company’s market capitalization to about $75.4 billion.A significant portion of that climb stems from encouraging Phase 3 data for intismeran autogene, the personalized melanoma therapy Moderna is co-developing with Merck. The stock has jumped roughly 222% since those interim findings were initially disclosed.Moderna now trades near its 52-week peak of $208.90. It’s a striking reversal for a company whose shares languished for years after post-pandemic vaccine revenue declined.Broader equity markets also provided a tailwind. The S&P 500 advanced 0.5%, the Dow Jones climbed 0.5%, and the Nasdaq rose 0.8% during the session. Meanwhile, competitors BioNTech and Pfizer barely moved, indicating this rally is company-specific rather than sector-driven.Skepticism Grows on Wall StreetNot all analysts share the market’s enthusiasm. Just before the Nasdaq-100 announcement, Citi’s Geoff Meacham lowered his rating on Moderna from Neutral to Sell.Though he lifted his price target from $60 to $80, the downgrade itself conveys a clear message: Meacham believes the stock has overextended.His case rests on valuation fundamentals. Citi calculates that Moderna would require approximately $13 billion in annual oncology revenue to support a $200 share price. That figure represents nearly seven times the firm’s current forecast for Moderna’s cancer franchise.Meacham described those implied revenue expectations as implausible.Yet buyers returned the following session, and the momentum has persisted into this week’s premarket trading, lifting shares once more.Across Wall Street, sentiment is mixed. Twenty analysts have issued ratings in the past three months, resulting in a Hold consensus for MRNA.The mean price target stands at $110.44, approximately 42% beneath the current trading level—a substantial divergence that highlights the sharp division among market watchers.In a separate development, Moderna recently established a Chief Operating Officer position, naming Juan Andres to lead the function. The appointment aims to support manufacturing expansion as the company’s oncology programs advance.Attention now turns to October 24, when Moderna will unveil fresh data at the ESMO conference. That presentation could serve as the next major inflection point for the stock’s trajectory.The post Moderna (MRNA) Jumps 2.2% in Premarket as Nasdaq-100 Entry Confirmed for October 9 appeared first on Blockonomi.